Market Overview

UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

Related FOLD
Earnings Scheduled For March 3, 2014
UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of Migalastat Monotherapy

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.

Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”

Amicus Therapeutics closed on Tuesday at $6.02.

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (FOLD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free